V.M. Grygorenko, O.V. Scherbina, S.S. Volkov, R.O. Danylets, M.V. Vikarchuk

Combined hormonal and radionuclide-medication therapy of prostate cancer

Aim. To improve the quality of providing specialized care to patients with prostate cancer by evaluation the effectiveness of the long-term results of different regimes of hormonal and radionuclide-medication therapy.

Matherials and methods. Was studied effectiveness of hormonal therapy in 246 patients with localized and advanced prostate cancer who received hormonal therapy under different regimes from 1997 to 2010.

Results. During treatment in all groups there was a decrease in the intensity of complaints, improvement of uroflowmetry, reduction of prostate volume and reduction of PSA without a significant difference between the indicated parameters among the groups. Indicators of general and cancers-specific survival and survival, depending on the presence of metastases between the groups, also did not differ statistically (p>0.05). In the treatment of patients with multiple bone metastasis was achieved long pain reduction (up to 10-12 months), with improvement of quality of life, motor activity, absence of pathological fractures and other complications.

Conclusions. Treatment in the LDEAT mode can achieve a significant therapeutic effect in a short time with less pronounced side effects. The dose reduction of flutamide does not reduce the overall and cancers-specific survival rates and improves the tolerability of treatment. In patients with multiple bone metastasis it was possible to achieve a significant therapeutic effect by the appointment of combined hormonal and radionuclide-medication therapy.